Abstract | BACKGROUND: METHODS AND RESULTS:
Celecoxib (10(-5) mol/L), but not rofecoxib (10(-7) to 10(-5) mol/L) or the experimental coxib NS-398 (10(-7) to 10(-5) mol/L), decreased tumor necrosis factor-alpha-induced TF expression and activity in human aortic endothelial cells. Celecoxib (10(-5) mol/L) reduced activation of c-jun terminal NH2 kinase (JNK), whereas it did not affect p38 mitogen-activated protein (MAP) kinase or p44/42 MAP kinase; in contrast, JNK activation was not affected by rofecoxib (10(-5) mol/L) or NS-398 (10(-5) mol/L). TF expression was reduced in a concentration-dependent manner by pretreatment with SP600125 (10(-7) to 10(-6) mol/L), a specific inhibitor of JNK, which confirms that JNK regulates tumor necrosis factor-alpha-induced TF expression. CONCLUSIONS:
Celecoxib reduced TF expression and activity in human aortic endothelial cells. Because neither rofecoxib nor the experimental coxib NS-398 affected TF expression, this effect occurs independently of COX-2 inhibition; it is rather mediated through inhibition of JNK phosphorylation. These data indicate a distinct heterogeneity within this class of drugs, which may be clinically relevant, especially for patients with atherosclerotic vascular diseases.
|
Authors | Jan Steffel, Matthias Hermann, Helen Greutert, Steffen Gay, Thomas F Lüscher, Frank Ruschitzka, Felix C Tanner |
Journal | Circulation
(Circulation)
Vol. 111
Issue 13
Pg. 1685-9
(Apr 05 2005)
ISSN: 1524-4539 [Electronic] United States |
PMID | 15795326
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cyclooxygenase Inhibitors
- Lactones
- Pyrazoles
- Sulfonamides
- Sulfones
- Tumor Necrosis Factor-alpha
- rofecoxib
- Thromboplastin
- JNK Mitogen-Activated Protein Kinases
- Mitogen-Activated Protein Kinases
- Celecoxib
|
Topics |
- Aorta
(cytology)
- Celecoxib
- Cells, Cultured
- Cyclooxygenase Inhibitors
(pharmacology)
- Endothelium, Vascular
(metabolism)
- Humans
- JNK Mitogen-Activated Protein Kinases
(antagonists & inhibitors, metabolism)
- Lactones
(pharmacology)
- Mitogen-Activated Protein Kinases
(analysis)
- Phosphorylation
(drug effects)
- Pyrazoles
(pharmacology)
- Signal Transduction
- Sulfonamides
(pharmacology)
- Sulfones
(pharmacology)
- Thromboplastin
(drug effects, genetics)
- Tumor Necrosis Factor-alpha
(pharmacology)
|